Skip to content
  1. Home
  2. >Clinical Genomics
  3. >Hereditary Cancer
  4. >Stat Brca1 And Brca2 Cancer Panel
Back to catalog

STAT BRCA1 and BRCA2 Cancer Panel

An expedited 2-gene panel for rapid evaluation of hereditary breast and ovarian cancer (HBOC) risk, delivering accelerated results powered by the Helix Exome+® platform.

Turnaround

6-11 days

Turnaround Requery

≤ 2 days

Panel Description

This STAT panel evaluates 2 genes associated with hereditary breast and ovarian cancer (HBOC) and delivers expedited results to enable accelerated clinical intervention.

View the complete description of this panel

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Indications for Testing

A relevant personal and/or family history suggestive of a hereditary form of cancer.

Methodology

This test utilizes next-generation sequencing to detect single nucleotide variants, insertions and deletions up to 20 bp, and copy number variants in genes associated with hereditary breast and ovarian cancer (HBOC).

Technical Specifications

Analytical sensitivity (SNV)> 99%Analytical sensitivity (indel)> 99%Analytical specificity> 99%CNV sensitivity (multi-exon)> 99%CNV sensitivity (single-exon)> 90%Gene notesBRCA1: sequencing analysis extends to CDS +/-20 bp; BRCA2: analysis includes detection of c.156_157insAlu and sequencing analysis extends to CDS +/-20 bp.Genomic buildGRCh38

Genes Tested

BRCA1
BRCA2

Showing 2 of 2 genes in this panel

Other Tests to Consider

Test

Hereditary Breast and Gynecologic Cancers Panel

21

genes

Test

BRCA1 and BRCA2 Panel

2

genes

Test

Hereditary Comprehensive Cancer Panel Plus

78

genes

Test

Hereditary Comprehensive Cancer Panel

70

genes

Important Panel Information

Turnaround time: Typically 7-11 days (standard), Typically < 2 days (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

This panel includes genes that have an established association with hereditary breast and ovarian cancer (HBOC).

The genes on this panel were specifically selected for their established association with hereditary cancer predisposition. Identification of a pathogenic variant may facilitate increased cancer screening and preventative surgery for early-detection and prevention. Identification of a pathogenic variant also helps identify at-risk family members, who can pursue genetic testing and preventive measures.

The genes on this panel are associated with conditions that have autosomal dominant and/or autosomal recessive inheritance. Note that some of these genes may also be associated with other unrelated conditions; this means that when undergoing this test, there is a possibility of incidentally detecting carrier status for, or predisposition to, one of these conditions.

Analyzing a wide range of genes in a single test can provide an efficient, cost-effective method of testing for several hereditary cancer conditions. This approach increases the chance of identifying the underlying diagnosis responsible for an individual’s or family’s cancer predisposition.

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.